Diseased PBMC and BMMC samples are occasionally collected at a different date from the initial sample utilized to establish blast percentages. Therefore, DLS is unable to guarantee blast percentages in diseased samples. However, for AML and multiple myeloma BMMCs, DLS performs flow cytometry following cryopreservation to characterize blast percentages, and these results are available to aid in sample selection.
Scalable Workflow for Single Nuclei Genomics and In Situ Hybridization
Save Big with Discovery’s Year-End Sales Event. Request a Quote While Supplies Last!
Navigate CDx complexity to accelerate your path to regulatory approval
NEW App Note: Optimized siRNA and mRNA Delivery in Primary Mouse Hepatocytes for Gene Therapy
Scalable Workflow for Single Nuclei Genomics and In Situ Hybridization
Save Big with Discovery’s Year-End Sales Event. Request a Quote While Supplies Last!
Navigate CDx complexity to accelerate your path to regulatory approval
NEW App Note: Optimized siRNA and mRNA Delivery in Primary Mouse Hepatocytes for Gene Therapy